Indications for Intravenous Immunoglobulin in Myasthenia Gravis

Acute/Severe Disease Indications

The American College of Physicians recommends IVIG 2 g/kg divided over 5 days (0.4 g/kg/day) for grade 3-4 toxicities requiring hospital admission with potential ICU monitoring, including patients with respiratory compromise and progressive myasthenia gravis that can lead to respiratory failure requiring mechanical ventilation 1, 2, 3
IVIG should be administered concurrently with corticosteroids in this setting, as recommended by the American College of Physicians 1, 2

The Mayo Clinic recommends IVIG at 1-2 g/kg of ideal body weight, given over 2 consecutive days (1 g/kg each day) once monthly for 1-6 months for patients with dysphagia, weight loss, or severe weakness, and checking serum IgA levels before administration to avoid severe anaphylaxis in IgA-deficient patients 4, 3
If IgA deficiency is detected, the Mayo Clinic recommends using IVIG preparations with reduced IgA levels to minimize the risk of anaphylaxis 4

The American Academy of Neurology recommends continuing IVIG 2 g/kg divided over 5 days in patients undergoing surgery, such as thymectomy, to maintain medical control of myasthenia gravis 3
IVIG may be preferred over plasma exchange due to easier administration, wider availability, and fewer complications, as suggested by the American Academy of Neurology 3

The standard acute dosing of IVIG is 2 g/kg divided over 5 days (0.4 g/kg/day), as recommended by the American College of Physicians 1, 2, 3
Alternative dosing includes 1-2 g/kg over 2 consecutive days for maintenance, as recommended by the Mayo Clinic 4

Frequent pulmonary function assessment with negative inspiratory force and vital capacity is recommended by the American College of Physicians to monitor patients receiving IVIG 1, 2, 3
Daily neurologic evaluation during acute treatment is recommended by the American College of Physicians to monitor disease progression and response to treatment 1, 2
Monitoring for infusion reactions, particularly in IgA-deficient patients, is recommended by the Mayo Clinic to minimize the risk of adverse events 4, 3

The American Academy of Neurology recommends repeat IVIG for patients with myasthenia gravis who have previously received IVIG treatment, particularly for acute exacerbations, treatment-related fluctuations, and as chronic maintenance therapy in refractory cases, with a strength of evidence rated as moderate to high 5

A single-day dosing regimen of 1 g/kg has been shown to be non-inferior to the standard 2 g/kg over 2 days for exacerbations, according to the National Institute of Neurological Disorders and Stroke 5

The American College of Surgeons recommends continuing IVIG 2 g/kg divided over 5 days in patients undergoing surgery, such as thymectomy, to maintain medical control of myasthenia gravis, with a strength of evidence rated as high 5

The FDA recommends always checking serum IgA levels before administering IVIG to avoid severe anaphylaxis in IgA-deficient patients, with a strength of evidence rated as high 5